EICHORPublic-registry site landscape for NCT02188368, “Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients”, a Multiple Myeloma study sponsored by Oncotherapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02188368 (registry record) |
| Study title | Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients |
| Official title | A Phase 2 Study of Pomalidomide as a Replacement for Lenalidomide for Multiple Myeloma Patients Relapsed or Refractory to a Lenalidomide-Containing Combination Regimen |
| Sponsor | Oncotherapeutics |
| Condition(s) | Multiple Myeloma |
| Phase | PHASE2 |
| Listed sites | 12 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02188368.
Eichor generates a preliminary site-risk snapshot for NCT02188368 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
